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Objective. Although systemic lupus erythematosus (SLE) is the most common autoimmune disease associated with 
antiphospholipid antibodies (aPL), limited data exist regarding the impact of SLE on the clinical phenotype of aPL- positive 
patients. The primary objective of this study was to compare the clinical, laboratory, and treatment characteristics of aPL- 
positive patients with SLE with those of aPL- positive patients without SLE.
Methods. A secure web- based data capture system was used to store patient demographic characteristics and aPL- 
related clinical and laboratory characteristics. Inclusion criteria included positive aPL according to the updated Sapporo clas-
sification criteria. Antiphospholipid antibody–positive patients fulfilling the American College of Rheumatology criteria for the 
classification of SLE (“aPL with SLE”) and those with no other autoimmune diseases (“aPL only”) were included in the analysis.
Results. Six hundred seventy- two aPL- positive patients were recruited from 24 international centers; 426 of these 
patients did not have other autoimmune disease, and 197 had SLE. The frequency of thrombocytopenia, hemolytic ane-
mia, low complement levels, and IgA anti–β2- glycoprotein I (anti- β2GPI) antibodies was higher in the aPL- positive patients 
with SLE, whereas the frequency of cognitive dysfunction and IgG anti- β2GPI antibodies was higher in the aPL- only group. 
The frequency of arterial and venous thromboses (including recurrent) as well as pregnancy morbidity was similar in the 
2 groups. The prevalence of cardiovascular disease risk factors at the time of entry into the registry entry did not differ 
between the 2 groups, with the exception of current smoking, which was more frequent in aPL- positive patients with SLE.
Conclusion. Although the frequencies of thrombosis and pregnancy morbidity are similar in aPL- positive patients with 
and those without SLE, the diagnosis of SLE in patients with persistently positive aPL is associated with an increased 
frequency of thrombocytopenia, hemolytic anemia, low complement levels, and positive IgA anti- β2GPI antibodies.
INTRODUCTION
Antiphospholipid syndrome (APS) is characterized by 
thromboses and/or pregnancy morbidity associated with per-
sistently positive antiphospholipid antibodies (aPL), lupus anti-
coagulant (LAC), anticardiolipin antibodies (aCL), and/or anti–
β2- glycoprotein I (anti- β2GPI) antibodies (1). Thrombocytopenia, 
autoimmune hemolytic anemia, livedo reticularis/racemosa, 
aPL- associated nephropathy, cardiac valve disease, cognitive 
dysfunction, and skin ulcers can also occur in aPL- positive pa-
tients (1,2), characterized as “non- criteria” APS manifestations.
APS can occur in individuals without an underlying systemic 
autoimmune disease (primary APS) or in the context of other 
systemic autoimmune diseases, with systemic lupus erythe-
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matosus (SLE) being the most common (30–50%) (3). Variable 
clinical features ranging from mild joint and skin involvement to 
life- threatening renal, hematologic, and/or central nervous sys-
tem manifestations can occur in patients with SLE. (4). Thirty 
percent to forty percent of SLE patients are positive for aPL (5); 
the prevalence of a “clinically significant” aPL profile (positive 
LAC test result based on the International Society of Thrombo-
sis and Hemostasis [ISTH] guidelines [6]), IgG/IgM aCL levels 
≥40 IgG phospholipid (GPL)/IgM phospholipid (MPL) units and/
or IgG/IgM anti- β2GPI levels ≥40 GPL/MPL units, tested twice at 
least 12 weeks apart is ~30% (7). Although persistently positive 
aPL has an impact on the clinical presentation and prognosis of 
patients with SLE (5), a limited number of studies have analyzed 
the impact of SLE on the clinical phenotype and prognosis of 
aPL- positive patients (8).
The AntiPhospholipid Syndrome Alliance for Clinical Trials 
and InternatiOnal Networking (APS ACTION) is an international 
network created to design and conduct large- scale, multicenter 
studies and clinical trials in patients with persistent aPL positivity 
(9). The APS ACTION clinical database and repository (“registry”) 
was created to study the natural disease course in patients with 
persistently positive aPL with or without autoimmune disorders 
over at least 10 years; the registry allows us to perform cross- 
sectional and prospective analyses.
In this international multicenter study, our primary objective 
was to compare the clinical, laboratory, and treatment character-
istics of aPL- positive patients with SLE and those without SLE. 
Second, we analyzed the frequencies of traditional cardiovascu-
lar disease (CVD) risk factors in aPL- positive patients with and 
those without SLE, and the pattern of use of hydroxychlor oquine 
(HCQ), an immunoregulatory agent with antithrombotic effects, 
among aPL- positive patients with no other autoimmune diseas-
es. We hypothesized that aPL- positive patients with SLE have 
increased rates of aPL- related clinical manifestations, traditional 
CVD risk factors, lupus- related antibodies, and immunosuppres-
sive use (including HCQ), compared with those without SLE.
PATIENTS AND METHODS
APS ACTION registry and data collection. An interna-
tional web- based application, Research electronic data capture 
(REDCap) (10), captures data on patient demographics, aPL- 
related clinical and laboratory characteristics, and medications. 
Data are collected once each year and at the time of a new aPL- 
related thrombosis or pregnancy morbidity. The inclusion criteria 
are age 18–60 years and persistent (at least 12 weeks apart) aPL 
positivity within 12 months prior to screening. Positivity is defined 
as the presence of IgG/IgM/IgA aCL at medium- to- high levels (≥40 
GPL/MPL/IgG antiphospholipid [APL] units and/or greater than the 
99th percentile) and/or the presence of IgG/IgM/IgA anti- β2GPI an-
tibodies at medium- to- high levels (≥40 GPL/MPL/APL units and/or 
greater than the 99th percentile), and/or positive LAC tests based 
on the ISTH guidelines (6). Patients are followed up every 12 ± 3 
(mean ± SD) months with clinical data and blood collection; they also 
receive advice on CVD and thrombosis prevention at each visit.
SIGNIFICANCE & INNOVATIONS
•  Although systemic lupus erythematosus (SLE) is 
the most common autoimmune disease associated 
with antiphospholipid antibodies (aPL), limited data 
exist regarding the impact of SLE on the clinical phe-
notype of aPL-positive patients.
•  Based on the analysis of a large-scale international 
registry, our study demonstrates that a concomitant 
SLE diagnosis in patients with persistently positive 
aPL does not increase the frequency of thrombo-
sis (including recurrent) and pregnancy morbidity. 
However, aPL-positive patients with SLE have an 
increased frequency of thrombocytopenia, hemo-
lytic anemia, low complement levels, and IgA anti–
β2-glycoprotein I antibody positivity compared with 
aPL-positive patients without other autoimmune 
diseases.
•  Additionally, aPL-positive patients with SLE had a 
significantly higher frequency of current smoking, 
while aPL-positive patients without other autoim-
mune diseases had an increased frequency of cog-
nitive dysfunction.
•  Although hydroxychloroquine (HCQ) use was more 
common in aPL-positive patients with SLE, 40% of 
aPL-positive patients with no other autoimmune 
diseases, especially those with lupus-related clinical 
and serologic manifestations, also received HCQ.
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Table 1. Clinical and laboratory characteristics (historic and/or at registry entry) of patients with persistent aPL positivity, overall and stratified 
by SLE*
Variables








patients with SLE 
(n = 197) P
Demographics
Age at entry into registry, mean ± SD years 44.2 ± 12.8 44.58 ± 12.9 43.24 ± 12.5 0.22
Female sex 459 (74) 307 (72) 152 (77) 0.18
Race†
White 397 (71) 274 (71) 123 (71)
Latin American Mestizos 81 (15) 66 (17) 15 (9)
Asian 48 (9) 28 (7) 20 (12)
Black 21(4) 10 (3) 11 (6)
American Indian or Alaskan Native 1 (0.2) 0 1 (0.6)
Reported as “other” 12 (2) 9 (2) 3 (2)
Ethnicity‡
US, Canada, Europe 261 (51) 183 (50) 78 (55)
Non–Latin American 242 (48) 168 (46) 74 (48)
Latin American 19 (4) 15 (4) 4 (3)
South America 124 (24) 96 (26) 28 (20)
Afro- descendant 16 (3) 8 (2) 8 (6)
Mestizo 67 (13) 54 (15) 13 (9)
Caucasian 41 (8) 34 (9) 7 (5)
Australia 3 (0.6) 2 (0.5) 1 (0.7)
Aboriginal 0 0 0
Not Aboriginal 3 (0.6) 2 (0.5) 1 (0.7)
Other 121 (24) 85 (23) 36 (24)
Clinical manifestations
Arterial thrombosis (AT) 193 (31) 139 (33) 54 (27) 0.26
Venous thrombosis (VT) 272 (44) 185 (43) 87 (44) 0.13
Microthrombosis (MT) 37 (6) 27 (6) 10 (5) 0.23
Any vascular event (AT/VT/MT) 422 (68) 297 (70) 125 (64) 0.12
Recurrent vascular event 198/422 (47) 163/297 (55) 61/125 (49) 0.25
Pregnancy (ever) 318 (51) 221(52) 97 (49) 0.06
Pregnancy morbidity 210 (34) 154 (36) 56 (28) 0.1
≥1 fetal death after 10th week of gestation 110 (18) 76 (18) 34 (17) 0.15
≥1 premature birth before 34th week of 
 gestation
54 (9) 43 (10) 11 (6) 0.09
≥3 consecutive unexplained spontaneous 
 abortions before 10th week of gestation
23 (4) 19 (5) 4 (2) 0.1
Catastrophic APS 6 (1) 4 (1) 2 (1) 0.24
Livedo reticularis/racemosa 80 (13) 52 (12) 28 (14) 0.48
Persistent thrombocytopenia 124 (20) 69 (16) 55 (28) 0.001
Autoimmune hemolytic anemia 32 (5) 9 (2) 23 (12) <0.001
ECG- proven cardiac valve disease 50/518 (10) 30/349 (9) 20/169 (12) 0.31
Biopsy- proven aPL- associated nephropathy 19/577 (3) 11/397 (3) 8/180 (4) 0.30
Skin ulcers 32 (5) 21 (5) 11 (6) 0.12
Cognitive dysfunction 19/148 (13) 14/90 (16) 5/58 (9) <0.001
(continued)
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Study cohort. Although the APS ACTION registry cap-
tures data for patients with a variety of autoimmune diseases, 
for the purpose of this analysis, patients with autoimmune dis-
eases other than SLE were excluded. Thus, 2 mutually exclu-
sive groups were included: aPL- positive patients with no other 
systemic autoimmune diseases (“aPL only”) and aPL- positive 
patients who also met the American College of Rheumatology 
(ACR) SLE classification criteria (“aPL with SLE”) (11).
Variables








patients with SLE 
(n = 197) P
Complement level
Low complement 3 (C3) level 93/240 (39) 29/126 (23) 64/114 (56) <0.001
Low complement 4 (C4) level 92/240 (38) 30/126 (24) 62/114 (54) <0.001
Antiphospholipid antibodies
Lupus anticoagulant (LAC) 417 (67) 288 (68) 129 (66) 0.6
Anticardiolipin antibody (aCL)
IgG (positive defined as ≥20 GPL) 357 (57) 245 (58) 15/89 (17) 0.87
IgG (positive defined as ≥40 GPL) 280 (45) 202 (47) 112 (57) 0.07
IgM (positive defined as ≥20 MPL) 223 (36) 154 (36) 78 (40) 0.79
IgM (positive defined as ≥40 MPL) 139 (22) 96 (23) 43 (22) 0.84
IgA (positive defined as ≥20 APL) 41/149 (28) 24/89 (27) 17/60 (28) 0.85
IgA (positive defined as ≥40 APL) 26/149 (17) 15/89 (17) 11/60 (18) 0.81
Anti- β2GPI§
IgG (positive defined as ≥20 GPL) 265 (43) 194 (46) 71 (36) 0.03
IgG (positive defined as ≥40 GPL) 208 (33) 157 (37) 51 (26) 0.01
IgM (positive defined as ≥20 MPL) 173 (28) 124 (29) 49 (25) 0.27
IgM (positive defined as ≥40 MPL) 114 (18) 81 (19) 33 (17) 0.5
IgA (positive defined as ≥20 APL) 58/160 (36) 30/104 (29) 28/56 (50) 0.02
IgA (positive defined as ≥40 APL) 37/160 (23) 19/104 (18) 18/56 (32) 0.04
Double aPL positive (LAC + aCL, LAC + anti- β2GPI, 
or aCL + anti- β2GPI)
187 (30) 121 (28) 66 (34) 0.1
Triple aPL positive (LAC + aCL + anti- β2GPI) 209 (34) 158 (37) 51 (26) 0.1
Medications at registry entry
Low- dose aspirin 273 (44) 183 (43) 90 (44) 0.52
Warfarin 344 (55) 245 (58) 99 (50) 0.09
Direct oral anticoagulants 15 (2) 10 (2) 5 (3) 0.89
Glucocorticoids 111 (18) 39 (9) 72 (37) <0.001
Hydroxychloroquine 276 (44) 133 (31) 143 (72) <0.001
Immunosuppressive agents
IV immunoglobulin 2 (0.3) 1 (0.2) 1 (1) 0.58
Rituximab 7 (1) 3 (1) 4 (2) 0.14
Azathioprine 46 (7) 11 (3) 35 (18) <0.001
Cyclophosphamide 8 (1) 2 (1) 6 (3) 0.008
Cyclosporine 4 (1) 2 (1) 2 (1) 0.43
Methotrexate 17 (3) 4 (1) 13 (7) <0.001
Mycophenolate mofetil 45 (7) 11 (3) 34 (17) <0.001
* Except where indicated otherwise, values are the number (%). aPL = antiphospholipid antibody; SLE = systemic lupus erythematosus; APS = 
antiphospholipid syndrome; ECG = electrocardiography; GPL = IgG phospholipid; MPL = IgM phospholipid; anti- β2GPI = anti–β2- glycoprotein I; 
LAC = lupus anticoagulant; IV = intravenous. 
† Information was collected for 560 patients (387 in the aPL only group and 173 in the aPL with SLE group). 
‡ Information was collected for 509 patients (366 in aPL only group and 143 in the aPL with SLE group). 
Table 1. (Cont’d)
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Covariates. We evaluated demographic characteris-
tics at the time of cohort entry, including mean age, race 
(white, Latin American Mestizos, Asian, black, American In-
dian or Alaskan, Native American, “other”), ethnicity (non–
Latin American or Latin American [for US, Canada, Europe], 
Afro- descendent, Mestizo, or Caucasian [for South America], 
Aboriginal or non- Aboriginal [for Australia], or “other”). Clini-
cal data retrieved were history of arterial and venous throm-
bosis, biopsy- proven microthrombosis (pulmonary, skin, kid-
ney, and “other”), pregnancy morbidity based on the updated 
Sapporo classification criteria, catastrophic APS based on 
the preliminary classification criteria (12), livedo reticularis/
racemosa, persistent thrombocytopenia (defined as a plate-
let count <100,000/μl [2 tests performed at least 12 weeks 
apart]), autoimmune hemolytic anemia, echocardiography- 
proven cardiac valve disease, biopsy- proven aPL nephrop-
athy, skin ulcers, and neuropsychiatric test–proven cognitive 
dysfunction. Laboratory data retrieved at baseline were aPL- 
related (LAC, IgG/IgM/IgA aCL, and IgG/IgM/IgA anti- β2GPI 
antibodies) and lupus- related antibodies (antinuclear anti-
body, anti–double- stranded DNA antibodies), anti- Sm, and 
complement components C3 and C4). Cardiovascular risk 
factors assessed at the time of entry into the registry were 
hypertension, diabetes mellitus, and hyperlipidemia requiring 
treatment; current and past smoking; estrogen use; obesity; 
family history of CVD; and sedentary lifestyle. Medications 
(low- dose aspirin, warfarin, direct oral anticoagulants, gluco-
corticoids, HCQ, intravenous immunoglobulin, rituximab, az-
athioprine, cyclophosphamide, cyclosporine, methotrexate, 
and mycophenolate mofetil) were included in the analysis as 
“ever used” or “never used.”
Statistical analysis. Data from the APS ACTION registry 
were locked in on February 2017. We compared the prevalence 
of covariates (historical or baseline) in the aPL only and aPL with 
SLE groups using the chi- square test for categorical variables. 
One- way analysis of variance was used to test the differences in 
means between multiple independent groups, and Student’s t- 
test was used for 2- group comparisons. We calculated 2- sided 
P values to determine the significance of all findings, with the 
significance level set at P < 0.05. Analyses were conducted us-
ing SPSS version 24.0.
RESULTS
As of February 2017, 672 aPL- positive patients were 
recruited from 24 centers; 43 patients (6%) were excluded 
due to underlying autoimmune diseases other than SLE, and 
6 (1%) were excluded due to missing data. Of the remaining 
623 patients, 426 did not have other autoimmune diseases 
(aPL only) and 197 had SLE (aPL with SLE). Fifty- nine patients 
in the aPL only group had SLE- like diseases (3 of 11 ACR SLE 
classification criteria were met) (11).
Table  1 shows the clinical, laboratory, and treatment 
characteristics collected at the time of entry into the registry. 
The mean ± SD age of the participants was 44.2 ± 12.8 years, 
and the majority of patients (74%) were categorized as white. 
Three hundred thirty- eight (79%) of 426 patients in the aPL 
only group and 137 (70%) of 426 patients in the aPL with SLE 
group were classified as having APS according to the updated 
Sapporo classification criteria (1). Overall, 422 (68%) of 623 
patients had a history of thrombotic APS, and 57 (9%) had 
obstetric APS only. The mean ± SD disease duration (time 
from the first available positive aPL test result to the enroll-
ment date) was similar in the 2 groups (5.6 ± 4.9 years in the 
aPL only group and 6.3 ± 5.1 years in the aPL with SLE group 
(P = 0.1).
Antiphospholipid antibody–positive patients with SLE had 
higher rates of persistent thrombocytopenia, autoimmune hemo-
lytic anemia, low C3 and C4 levels, and IgA anti- β2GPI antibody 
positivity, whereas the aPL only group had significantly higher 
rates of cognitive dysfunction and IgG anti- β2GPI antibody pos-
itivity. Glucocorticoids, HCQ, azathioprine, cyclophosphamide, 
methotrexate, and mycophenolate mofetil were more frequently 
used in the aPL with SLE group.
The prevalence of traditional CVD risk factors at the time 
of entry into the registry did not differ between the 2 groups, 
with the exception of current smoking, which was more fre-
quent in aPL- positive SLE patients (15% versus 9% in the 
aPL only group; P = 0.03) (Table 2). In the aPL only group, 
262 patients (62%) were never treated with HCQ, 133 (31%) 
were current users (200–400 mg daily), and 31 (7%) were 
past users; 99 (74%) of the 133 current users and 26 (84%) 
of the 31 past users were classified as having APS. Patients 
with lupus- related clinical manifestations, low C4 levels, and 
lupus- related autoantibodies were more likely to be treated 
with HCQ (Table 3). After patients with SLE- like diseases (i.e., 
3 of 11 ACR classification criteria for SLE were met) (n = 59) 
were excluded, when we analyzed 367 patients in the aPL 
only group, we observed a higher frequency of HCQ treat-
ment in patients with low C4 levels and lupus- related autoan-
tibodies.
DISCUSSION
Based on the analysis of a large- scale international regis-
try of patients with persistently positive aPL, our study demon-
strated that the frequencies of thrombosis (including recurrent) 
and pregnancy morbidity were similar between aPL- positive 
patients with SLE and aPL- positive patients without SLE. How-
ever, a concomitant SLE diagnosis in patients with persistent 
aPL positivity was associated with an increased frequency of 
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 thrombocytopenia, hemolytic anemia, low C3 and C4 levels, and 
IgA anti- β2GPI antibody positivity compared with the frequen-
cy in aPL- positive patients without other autoimmune diseases. 
Additionally, aPL- positive patients with SLE had a significantly 
higher frequency of current smoking, while aPL- positive patients 
without other autoimmune diseases had an increased prev-
alence of cognitive dysfunction. Although HCQ use was more 
common in the aPL with SLE group, 40% of the aPL only group 
also received HCQ, especially those with lupus- related clinical 
and serologic manifestations.
Although the impact of aPL on SLE is well studied (5,7), 
limited data exist regarding the impact of SLE on the clinical phe-
notype of patients with persistently positive aPL. In a European 
multicenter cohort of 1,000 mainly Caucasian patients with APS, 
patients with concomitant SLE had a higher prevalence of livedo 
reticularis, thrombocytopenia, arthritis, and leukopenia (13). Our 
multiethnic study also showed an increased frequency of throm-
bocytopenia and autoimmune hemolytic anemia in aPL- positive 
patients with SLE compared with the frequency in those without 
SLE; however, with the exception of cognitive dysfunction, sim-
ilar frequencies of the classification criteria or other non- criteria 
aPL manifestations, namely livedo reticularis, cardiac valve dis-
ease, and aPL- associated nephropathy, were observed in the 
2 groups. Given that our SLE patients were classified based on 
the ACR classification criteria (11), which incorporate thrombo-
cytopenia and autoimmune hemolytic anemia, the increased 
frequency of these hematologic abnormalities in aPL- positive 
patients with SLE was not unexpected.
Cognitive dysfunction is common in APS and SLE and is 
frequently associated with livedo reticularis and white matter 
lesions on brain magnetic resonance imaging in patients with 
APS. Tektonidou et al previously showed no difference in cog-
nitive performance as assessed by a 3- hour battery of neuro-
cognitive tests among patients with primary APS and those with 
SLE and APS (14). Kozora et al demonstrated that 12 (60%) of 
Table  2. Prevalence of CVD and thrombosis risk factors at the 
time of registry entry among patients with persistent aPL positivity, 




aPL with SLE 
(n = 197) P
Hypertension 118 (28) 66 (34) 0.14
Diabetes 22 (5) 8 (4) 0.55
Hyperlipidemia 103 (24) 36 (18) 0.1
Smoking ever 116 (27) 49 (25) 0.65
Current smoking 40 (9) 30 (15) 0.03
Estrogen use 3 (1) 3 (2) 0.54
Obesity 107 (25) 59 (30) 0.37
Family history of 
CVD
67 (16) 21 (11) 0.18
Sedentary 
lifestyle
197 (46) 94 (48) 0.73
* Values are the number (%). CVD = cardiovascular disease; aPL = 
antiphospholipid antibody; SLE = systemic lupus erythematosus. 




No HCQ use 
(n = 262) P
Clinical profile
Thrombotic APS 89 (54) 148 (57) 0.65
Arterial thrombosis 52 (32) 87 (33) 0.84
Venous thrombosis 75 (46) 110 (42) 0.3
Microthrombosis 11 (7) 16 (6) 0.74
Obstetric APS 16 (10) 28 (11) 0.76
Thrombotic and obstetric APS 21 (13) 37 (14) 0.70
3 of 11 ACR SLE criteria met 42 (26) 17 (7) <0.001
Laboratory profile
Persistent triple aPL positive 60 (37) 98 (37) 0.87
Persistent double aPL positive 50 (30) 97 (27) 0.1
Persistent single aPL positive 102 (62) 67 (26) 0.16
ANA positive 30 (18) 86 (33) <0.001
Anti- dsDNA positive 5 (3) 10 (4) <0.001
Anti- Sm positive 17/66 (26) 0 (0) 0.008
Low complement 3 (C3) level 54 (33) 12/60 (20) 0.44
Low complement 4 (C4) level 20/66 (30) 10/60 (17) 0.02
* Patients were considered to be positive for antinuclear antibodies (ANAs), anti–double- stranded DNA (anti- dsDNA), or anti- Sm if they ever 
had a positive test result for these antibodies. A low C3 or C4 level was based on a level below normal and the most recent C3/4 tests before 
registry entry. Values are the number/number assessed (%). aPL = antiphospholipid antibody; HCQ = hydroxychloroquine; APS = aPL syn-
drome; ACR = American College of Rheumatology; SLE = systemic lupus erythematosus. 
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20  aPL- positive SLE patients and 8 (40%) of 20 aPL- positive 
patients without SLE had global cognitive impairment on a ACR- 
SLE cognitive impairment index, which is a validated neuropsy-
chologic instrument; there were no group differences on the cog-
nitive impairment index or on individual measures (15). Our study 
included SLE patients with persistently positive aPL and aPL- 
positive patients who did not meet the APS classification criteria 
(1) and still showed that neuropsychiatric test–proven cognitive 
dysfunction was more common in aPL- positive patients without 
SLE. These findings further support the importance of research 
for cognitive dysfunction and clinical assessment in aPL- positive 
patients without other systemic autoimmune diseases.
The updated Sapporo criteria for the classification of APS do 
not include IgA aCL and IgA anti- β2GPI antibodies. Although the 
IgA isotype is common in black patients with SLE (16) and now is 
included in the revised Systemic Lupus International Collaborat-
ing Clinics criteria for the classification of SLE (17), the prevalence 
and clinical significance of this isotype have been controversial 
(18). We observed that although aPL types and isotypes as 
well as double or triple aPL positivity were generally compara-
ble  between the 2 groups, aPL- positive patients with SLE more 
frequently had IgA anti- β2GPI antibodies, while IgG anti- β2GPI 
antibodies were more frequent in those without SLE. Although it 
remains unknown why patients develop different isotypes of aPL, 
our findings support those of previous studies (19), thus demon-
strating the potential diagnostic and clinical significance of the 
IgA isotype in lupus patients compared with those without lupus.
Traditional CVD risk factors, including diabetes mellitus and 
smoking, increase the risk of thrombosis in aPL- positive patients 
(20). SLE itself is an independent risk factor for CVD, which re-
mains the major cause of mortality in patients with SLE (21). It is 
not well- studied whether CVD risk factors differ between aPL- 
positive patients with SLE and those without SLE; our study 
demonstrated that the prevalence of CVD risk factors was similar 
between aPL- positive patients with and those without SLE, with 
the exception of current smoking. In addition, although the role of 
smoking in the development of aPL, APS, and/or SLE is not well- 
established (22), smoking is associated with worse outcomes 
and venous thrombosis in patients with SLE as well as the devel-
opment of SLE subtypes, as defined by autoantibody status (23). 
All of these findings support the importance of similar diligence in 
CVD risk assessment and management measures in both aPL- 
positive patients with SLE and aPL- positive patients without SLE.
In our study, use of glucocorticoids, HCQ, azathioprine, cy-
clophosphamide, methotrexate, and mycophenolate mofetil was 
more frequent in aPL- positive patients with SLE compared with 
aPL- positive patients without SLE at the time of entry into the 
cohort. Use of HCQ in patients with SLE is well- established; 
however, no strong clinical data exist to recommend HCQ treat-
ment for aPL- positive patients without other systemic autoim-
mune diseases. Given animal and in vitro studies showing that 
HCQ has a potential antithrombotic role in addition to its immu-
noregulatory and metabolic effects (24–29), HCQ has been used 
in some centers to prevent thrombosis in aPL- positive patients 
without other systemic autoimmune diseases (30–32). An inter-
national study aimed at determining the effectiveness of HCQ 
for thrombosis prevention in asymptomatic aPL- positive pa-
tients was terminated early for reasons related to logistics (33). 
In the current study, ~40% of aPL- positive patients without other 
systemic autoimmune diseases reported HCQ use, and the fre-
quency of serologic features of SLE was higher in aPL- positive 
patients using HCQ. Our study was not designed to determine 
the prophylactic role of HCQ; however, we believe that prospec-
tive follow- up of patients in our registry will provide further valu-
able data on outcomes in HCQ- treated aPL- positive patients.
Although our study was limited due to its retrospective, 
cross- sectional study design, we used a large, multicenter, in-
ternational patient cohort. Our data set is enriched by inclusion 
of granular sociodemographic, clinical, laboratory, and medica-
tion data. However, data for CVD risk factors were collected at 
the time of the patient’s enrollment and not at the time of the 
thrombotic event, which may have resulted in inaccurate CVD 
prevalence estimates in different groups of aPL- positive patients.
In conclusion, our analysis of a large, multicenter, inter-
national cohort of patients who are persistently aPL- positive 
demonstrates an increased frequency of thrombocytopenia, 
hemolytic anemia, low complement levels, and IgA anti- β
2GPI 
antibody positivity but not the risk of thrombotic, obstetric, and 
non- criteria APS manifestations (except cognitive dysfunction) 
among aPL- positive patients with a concomitant SLE diagnosis 
compared with those without SLE. Our exploratory study pro-
vides pilot data for future risk- stratified prospective analyses us-
ing the APS ACTION registry, which will better determine the clin-
ical impact of SLE on the presentation of aPL- positive  patients.
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